IMUX

Immunic (IMUX)

About Immunic (IMUX)

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company was founded in May 2003 and is headquartered in New York, NY.

Details

Daily high

$0.63

Daily low

$0.60

Price at open

$0.61

52 Week High

$1.39

52 Week Low

$0.56

Market cap

73.8M

Dividend yield

0.00%

Volume

1.5M

Avg. volume

1.3M

P/E ratio

-.71

Immunic News